Marco Rusnati

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2379474/publications.pdf

Version: 2024-02-01

159 papers	9,173 citations	34105 52 h-index	46799 89 g-index
160 all docs	160 docs citations	160 times ranked	9842 citing authors

#	Article	IF	Citations
1	Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine and Growth Factor Reviews, 2005, 16, 159-178.	7.2	1,126
2	Internalization of HIV-1 Tat Requires Cell Surface Heparan Sulfate Proteoglycans. Journal of Biological Chemistry, 2001, 276, 3254-3261.	3.4	635
3	Complexity and Complementarity of Outer Membrane Protein A Recognition by Cellular and Humoral Innate Immunity Receptors. Immunity, 2005, 22, 551-560.	14.3	271
4	Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood, 2004, 104, 92-99.	1.4	181
5	Interaction of HIV-1 Tat Protein with Heparin. Journal of Biological Chemistry, 1997, 272, 11313-11320.	3.4	179
6	Role of the soluble pattern recognition receptor PTX3 in vascular biology. Journal of Cellular and Molecular Medicine, 2007, 11, 723-738.	3.6	166
7	Endogenous Basic Fibroblast Growth Factor Is Implicated in the Vascularization of the Chick Embryo Chorioallantoic Membrane. Developmental Biology, 1995, 170, 39-49.	2.0	158
8	Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach. , 2017, 179, 171-187.		152
9	Î±_vÎ²₃Integrin Mediates the Cell-adhesive Capacity and Biological Activity of Basic Fibroblast Growth Factor (FGF-2) in Cultured Endothelial Cells. Molecular Biology of the Cell, 1997, 8, 2449-2461.	2.1	140
10	Basic fibroblast growth factor is released from endothelial extracellular matrix in a biologically active form. Journal of Cellular Physiology, 1989, 140, 68-74.	4.1	137
11	Fibroblast Growth Factors/Fibroblast Growth Factor Receptors as Targets for the Development of Anti-Angiogenesis Strategies. Current Pharmaceutical Design, 2007, 13, 2025-2044.	1.9	134
12	Heparin/Heparan Sulfate Proteoglycans Glycomic Interactome in Angiogenesis: Biological Implications and Therapeutical Use. Molecules, 2015, 20, 6342-6388.	3.8	126
13	Cutting Edge: Proangiogenic Properties of Alternatively Activated Dendritic Cells. Journal of Immunology, 2005, 175, 2788-2792.	0.8	124
14	Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans. International Journal of Clinical and Laboratory Research, 1996, 26, 15-23.	1.0	121
15	Dendritic cellâ€“endothelial cell cross-talk in angiogenesis. Trends in Immunology, 2007, 28, 385-392.	6.8	115
16	Multiple Interactions of HIV-I Tat Protein with Size-defined Heparin Oligosaccharides. Journal of Biological Chemistry, 1999, 274, 28198-28205.	3.4	110
17	Basic Fibroblast Growth Factorâ€“Induced Angiogenic Phenotype in Mouse Endothelium. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 454-464.	2.4	108
18	The Basic Domain in HIV-1 Tat Protein as a Target for Polysulfonated Heparin-mimicking Extracellular Tat Antagonists. Journal of Biological Chemistry, 1998, 273, 16027-16037.	3.4	105

#	Article	IF	Citations
19	Heparin Derivatives as Angiogenesis Inhibitors. Current Pharmaceutical Design, 2003, 9, 553-566.	1.9	102
20	Cell membrane GM1 ganglioside is a functional coreceptor for fibroblast growth factor 2. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 4367-4372.	7.1	101
21	Identification of an Antiangiogenic FGF2-binding Site in the N Terminus of the Soluble Pattern Recognition Receptor PTX3. Journal of Biological Chemistry, 2006, 281, 22605-22613.	3.4	101
22	Pradimicin A, a Carbohydrate-Binding Nonpeptidic Lead Compound for Treatment of Infections with Viruses with Highly Glycosylated Envelopes, Such as Human Immunodeficiency Virus. Journal of Virology, 2007, 81, 362-373.	3.4	99
23	Modulation of Fibroblast Growth Factor-2 Receptor Binding, Signaling, and Mitogenic Activity by Heparin-Mimicking Polysulfonated Compounds. Molecular Pharmacology, 1999, 56, 204-213.	2.3	95
24	HIV-1 Tat protein and endothelium: from protein/cell interaction to AIDS-associated pathologies. Angiogenesis, 2002, 5, 141-151.	7.2	93
25	Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. Blood, 2003, 102, 4399-4406.	1.4	93
26	Pentraxin 3 Inhibits Fibroblast Growth Factor 2â€“Dependent Activation of Smooth Muscle Cells In Vitro and Neointima Formation In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1837-1842.	2.4	93
27	HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 14580-14585.	7.1	92
28	Internalization of basic fibroblast growth factor (bFGF) in cultured endothelial cells: Role of the low affinity heparin-like bFGF receptors. Journal of Cellular Physiology, 1993, 154, 152-161.	4.1	85
29	Distinct Role of 2-O-, N-, and 6-O-Sulfate Groups of Heparin in the Formation of the Ternary Complex with Basic Fibroblast Growth Factor and Soluble FGF Receptor-1. Biochemical and Biophysical Research Communications, 1994, 203, 450-458.	2.1	85
30	Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis. International Journal of Clinical and Laboratory Research, 1998, 28, 55-68.	1.0	85
31	Sulfated K5 Escherichia coli polysaccharide derivatives: A novel class of candidate antiviral microbicides. , 2009, 123, 310-322.		82
32	Undersulfated and Glycol-Split Heparins Endowed with Antiangiogenic Activity. Journal of Medicinal Chemistry, 2004, 47, 838-848.	6.4	80
33	The discovery of basic fibroblast growth factor/fibroblast growth factor-2 and its role in haematological malignancies. Cytokine and Growth Factor Reviews, 2007, 18, 327-334.	7.2	78
34	A six-amino acid deletion in basic fibroblast growth factor dissociates its mitogenic activity from its plasminogen activator-inducing capacity.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 2628-2632.	7.1	76
35	Short Heparin Sequences Spaced by Glycol-Split Uronate Residues Are Antagonists of Fibroblast Growth Factor 2 and Angiogenesis Inhibitors. Biochemistry, 2002, 41, 10519-10528.	2.5	76
36	Fibroblast Growth Factor-2 Antagonist Activity and Angiostatic Capacity of Sulfated Escherichia coli K5 Polysaccharide Derivatives. Journal of Biological Chemistry, 2001, 276, 37900-37908.	3.4	73

#	Article	IF	Citations
37	The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis. Expert Opinion on Therapeutic Targets, 2015, 19, 1361-1377.	3.4	72
38	Membrane association of peroxiredoxin-2 in red cells is mediated by the N-terminal cytoplasmic domain of band 3. Free Radical Biology and Medicine, 2013, 55, 27-35.	2.9	71
39	Non-peptidic Thrombospondin-1 Mimics as Fibroblast Growth Factor-2 Inhibitors. Journal of Biological Chemistry, 2010, 285, 8733-8742.	3.4	70
40	Blocking the FGF/FGFR system as a â¿¿two-compartmentâ¿¿ antiangiogenic/antitumor approach in cancer therapy. Pharmacological Research, 2016, 107, 172-185.	7.1	69
41	Pentosan Polysulfate as an Inhibitor of Extracellular HIV-1 Tat. Journal of Biological Chemistry, 2001, 276, 22420-22425.	3.4	67
42	Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain. International Journal of Biochemistry and Cell Biology, 2008, 40, 700-709.	2.8	67
43	Interaction of high-molecular-weight basic fibroblast growth factor with endothelium: Biological activity and intracellular fate of human recombinant Mr 24,000 bFGF. Journal of Cellular Physiology, 1994, 161, 149-159.	4.1	66
44	Interaction of Fibroblast Growth Factor-2 (FGF-2) with Free Gangliosides: Biochemical Characterization and Biological Consequences in Endothelial Cell Cultures. Molecular Biology of the Cell, 1999, 10, 313-327.	2.1	65
45	Activation of Hsp90 Enzymatic Activity and Conformational Dynamics through Rationally Designed Allosteric Ligands. Chemistry - A European Journal, 2015, 21, 13598-13608.	3.3	65
46	Basic fibroblast growth factor requires a long-lasting activation of protein kinase C to induce cell proliferation in transformed fetal bovine aortic endothelial cells.. Molecular Biology of the Cell, 1991, 2, 719-726.	6.5	64
47	Merging colloidal nanoplasmonics and surface plasmon resonance spectroscopy for enhanced profiling of multiple myeloma-derived exosomes. Biosensors and Bioelectronics, 2016, 77, 518-524.	10.1	63
48	Heparan Sulfate Proteoglycans Mediate the Angiogenic Activity of the Vascular Endothelial Growth Factor Receptor-2 Agonist Gremlin. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, e116-27.	2.4	62
49	Biological activity of substrate-bound basic fibroblast growth factor (FGF2): recruitment of FGF receptor-1 in endothelial cell adhesion contacts. Oncogene, 2002, 21, 3889-3897.	5.9	61
50	Purification of basic fibroblast growth factor from rat brain: Identification of a Mr 22,000 immunoreactive form. Biochemical and Biophysical Research Communications, 1988, 155, 1161-1172.	2.1	57
51	Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors. Oncotarget, 2010, 1, 662-673.	1.8	57
52	The binding of heparin to spike glycoprotein inhibits SARS-CoV-2 infection by three mechanisms. Journal of Biological Chemistry, 2022, 298, 101507.	3.4	57
53	Identification of a Dendrimeric Heparan Sulfate-Binding Peptide That Inhibits Infectivity of Genital Types of Human Papillomaviruses. Antimicrobial Agents and Chemotherapy, 2010, 54, 4290-4299.	3.2	56
54	Biochemical bases of the interaction of human basic fibroblast growth factor with glycosaminoglycans. New insights from trypsin digestion studies. FEBS Journal, 1993, 214, 51-58.	0.2	52

#	Article	IF	Citations
55	Fibroblast Growth Factors and Their Receptors in Hematopoiesis and Hematological Tumors. Journal of Hematotherapy and Stem Cell Research, 2002, 11, 19-32.	1.8	52
56	Biotechnological Engineering of Heparin/Heparan Sulphate: A Novel Area of Multi-Target Drug Discovery. Current Pharmaceutical Design, 2005, 11, 2489-2499.	1.9	52
57	Basic fibroblast growth factor: Production, mitogenic response, and post-receptor signal transduction in cultured normal and transformed fetal bovine aortic endothelial cells. Journal of Cellular Physiology, 1989, 141, 517-526.	4.1	50
58	Chemically sulfatedEscherichia coliK5 polysaccharide derivatives as extracellular HIV-1 Tat protein antagonists. FEBS Letters, 2004, 568, 171-177.	2.8	50
59	Basic Fibroblast Growth Factor in Ovulatory Cycle and Postmenopausal Human Endometrium. Growth Factors, 1990, 3, 299-307.	1.7	49
60	Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist. Glycobiology, 2004, 15, 1C-6C.	2.5	48
61	Î±vÎ²3-integrin-dependent activation of focal adhesion kinase mediates NF-ÎºB activation and motogenic activity by HIV-1 Tat in endothelial cells. Journal of Cell Science, 2005, 118, 3949-3958.	2.0	47
62	Inhibition of Human Respiratory Syncytial Virus Infectivity by a Dendrimeric Heparan Sulfate-Binding Peptide. Antimicrobial Agents and Chemotherapy, 2012, 56, 5278-5288.	3.2	47
63	Polyanionic Drugs and Viral Oncogenesis: a Novel Approach to Control Infection, Tumor-associated Inflammation and Angiogenesis. Molecules, 2008, 13, 2758-2785.	3.8	46
64	Heparin-Mimicking Sulfonic Acid Polymers as Multitarget Inhibitors of Human Immunodeficiency Virus Type 1 Tat and gp120 Proteins. Antimicrobial Agents and Chemotherapy, 2007, 51, 2337-2345.	3.2	45
65	Thrombospondin-1 inhibits Kaposi's sarcoma (KS) cell and HIV-1 Tat-induced angiogenesis and is poorly expressed in KS lesions. , 1999, 188, 76-81.		44
66	Integrin Î±VÎ²3as a Target for Blocking HIV-1 Tat-Induced Endothelial Cell Activation In Vitro and Angiogenesis In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 2315-2320.	2.4	44
67	A complex of Î±₆ integrin and Eâ€cadherin drives liver metastasis of colorectal cancer cells through hepatic angiopoietinâ€like 6. EMBO Molecular Medicine, 2012, 4, 1156-1175.	6.9	44
68	Extracellular Angiogenic Growth Factor Interactions: An Angiogenesis Interactome Survey. Endothelium: Journal of Endothelial Cell Research, 2006, 13, 93-111.	1.7	43
69	Sulfated K5 Escherichia coli Polysaccharide Derivatives as Wide-Range Inhibitors of Genital Types of Human Papillomavirus. Antimicrobial Agents and Chemotherapy, 2008, 52, 1374-1381.	3.2	43
70	HIV-1 matrix protein p17 binds to the IL-8 receptor CXCR1 and shows IL-8â€“like chemokine activity on monocytes through Rho/ROCK activation. Blood, 2012, 119, 2274-2283.	1.4	43
71	Promotion of tumour metastases and induction of angiogenesis by native HIV-1 Tat protein from BK virus/tat transgenic mice. Aids, 1996, 10, 701-710.	2.2	42
72	HIV-1 Tat and heparan sulfate proteoglycan interaction: a novel mechanism of lymphocyte adhesion and migration across the endothelium. Blood, 2009, 114, 3335-3342.	1.4	42

#	Article	IF	Citations
73	Characterization of a Mr 25,000 basic fibroblast growth factor form in adult, regenerating, and fetal rat liver. Biochemical and Biophysical Research Communications, 1989, 164, 1182-1189.	2.1	41
74	Activation of Endothelial Cell Mitogen Activated Protein Kinase ERK_{1/2}by Extracellular HIV-1 Tat Protein. Endothelium: Journal of Endothelial Cell Research, 2001, 8, 65-74.	1.7	40
75	Direct and Allosteric Inhibition of the FGF2/HSPGs/FGFR1 Ternary Complex Formation by an Antiangiogenic, Thrombospondin-1-Mimic Small Molecule. PLoS ONE, 2012, 7, e36990.	2.5	40
76	Î”5-Cholenoyl-amino acids as selective and orally available antagonists of the Ephâ€“ephrin system. European Journal of Medicinal Chemistry, 2015, 103, 312-324.	5.5	38
77	Polysulfated/Sulfonated Compounds for the Development of Drugs at the Crossroad of Viral Infection and Oncogenesis. Current Pharmaceutical Design, 2009, 15, 2946-2957.	1.9	37
78	The calcium-binding type III repeats domain of thrombospondin-2 binds to fibroblast growth factor 2 (FGF2). Angiogenesis, 2019, 22, 133-144.	7.2	37
79	The FGF/FGFR system in the physiopathology of the prostate gland. Physiological Reviews, 2021, 101, 569-610.	28.8	37
80	Alterations of blood vessel development by endothelial cells overexpressing fibroblast growth factor-2. , 1999, 189, 590-599.		35
81	Antiangiogenic Activity of Semisynthetic Biotechnological Heparins. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 71-76.	2.4	35
82	Multispot, label-free biodetection at a phantom plasticâ€“water interface. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9350-9355.	7.1	35
83	Highly Sulfated K5 Escherichia coli Polysaccharide Derivatives Inhibit Respiratory Syncytial Virus Infectivity in Cell Lines and Human Tracheal-Bronchial Histocultures. Antimicrobial Agents and Chemotherapy, 2014, 58, 4782-4794.	3.2	35
84	High molecular weight immunoreactive basic fibroblast growth factor-like proteins in rat pituitary and brain. Neuroscience Letters, 1988, 90, 308-313.	2.1	34
85	A natural HIV p17 protein variant up-regulates the LMP-1 EBV oncoprotein and promotes the growth of EBV-infected B-lymphocytes: Implications for EBV-driven lymphomagenesis in the HIV setting. International Journal of Cancer, 2015, 137, 1374-1385.	5.1	34
86	Modulation of plasminogen activator activity in human endometrial adenocarcinoma cells by basic fibroblast growth factor and transforming growth factor beta. Cancer Research, 1988, 48, 6384-9.	0.9	34
87	Basic fibroblast growth factor in human pheochromocytoma: A biochemical and immunohistochemical study. International Journal of Cancer, 1993, 53, 5-10.	5.1	33
88	Fibroblast Growth Factor-2 Antagonist and Antiangiogenic Activity of Long-Pentraxin 3-Derived Synthetic Peptides. Current Pharmaceutical Design, 2009, 15, 3577-3589.	1.9	33
89	Contribution of vascular endothelial growth factor receptor-2 sialylation to the process of angiogenesis. Oncogene, 2017, 36, 6531-6541.	5.9	33
90	Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors. Oncotarget, 2010, 1, 662-73.	1.8	33

#	Article	IF	Citations
91	Biologically active synthetic fragments of human basic fibroblast growth factor (bFGF): Identification of two Asp-Gly-Arg-Containing domains involved in the mitogenic activity of bFGF in endothelial cells. Journal of Cellular Physiology, 1991, 149, 512-524.	4.1	32
92	Peptide-Derivatized SB105-A10 Dendrimer Inhibits the Infectivity of R5 and X4 HIV-1 Strains in Primary PBMCs and Cervicovaginal Histocultures. PLoS ONE, 2013, 8, e76482.	2.5	32
93	Structure-function relationship of basic fibroblast growth factor: Site-directed mutagenesis of a putative heparin-binding and receptor-binding region. Biochemical and Biophysical Research Communications, 1992, 185, 1098-1107.	2.1	31
94	Inhibition of Non Canonical HIV-1 Tat Secretion Through the Cellular Na + ,K + -ATPase Blocks HIV-1 Infection. EBioMedicine, 2017, 21, 170-181.	6.1	31
95	Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action. Pharmaceuticals, 2010, 3, 1241-1278.	3.8	30
96	Molecular Interaction Studies of HIV-1 Matrix Protein p17 and Heparin. Journal of Biological Chemistry, 2013, 288, 1150-1161.	3.4	30
97	The AGMA1 poly(amidoamine) inhibits the infectivity of herpes simplex virus in cell lines, in human cervicovaginal histocultures, and in vaginally infected mice. Biomaterials, 2016, 85, 40-53.	11.4	30
98	UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice. Oncotarget, 2018, 9, 24347-24363.	1.8	28
99	Thrombospondinâ€1/HIVâ€1 Tat protein interaction: modulation of the biological activity of extracellular Tat. FASEB Journal, 2000, 14, 1917-1930.	0.5	27
100	Sialic Acid Associated with Î±vÎ²3 Integrin Mediates HIV-1 Tat Protein Interaction and Endothelial Cell Proangiogenic Activation. Journal of Biological Chemistry, 2012, 287, 20456-20466.	3.4	26
101	Angiogenic growth factors interactome and drug discovery: The contribution of surface plasmon resonance. Cytokine and Growth Factor Reviews, 2015, 26, 293-310.	7.2	26
102	Characterization of a Mr 20,000 basic fibroblast growth factor-like protein secreted by normal and transformed fetal bovine aortic endothelial cells. Experimental Cell Research, 1990, 186, 354-361.	2.6	24
103	Simian Immunodeficiency Virus and Human Immunodeficiency Virus Type 1 Matrix Proteins Specify Different Capabilities To Modulate B Cell Growth. Journal of Virology, 2014, 88, 5706-5717.	3.4	23
104	Estro-Progestinic Replacement Therapy Modulates the Levels of Basic Fibroblast Growth Factor (bFGF) in Postmenopausal Endometrium. Gynecologic Oncology, 1993, 48, 88-93.	1.4	22
105	Bridging the past and the future of virology: Surface plasmon resonance as a powerful tool to investigate virus/host interactions. Critical Reviews in Microbiology, 2015, 41, 238-260.	6.1	22
106	HIV-1 Tat protein: A target for the development of anti-AIDS therapies. Drugs of the Future, 2002, 27, 481.	0.1	21
107	The Agmatine-Containing Poly(Amidoamine) Polymer AGMA1 Binds Cell Surface Heparan Sulfates and Prevents Attachment of Mucosal Human Papillomaviruses. Antimicrobial Agents and Chemotherapy, 2015, 59, 5250-5259.	3.2	20
108	Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors. Scientific Reports, 2016, 6, 23432.	3.3	20

#	Article	IF	Citations
109	Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction. Biochemical Pharmacology, 2018, 147, 21-29.	4.4	20
110	Identification of amino acid residues critical for the B cell growth-promoting activity of HIV-1 matrix protein p17 variants. Biochimica Et Biophysica Acta - General Subjects, 2019, 1863, 13-24.	2.4	20
111	Up-regulation of urokinase-type plasminogen activator in squamous cell carcinoma of human larynx. British Journal of Cancer, 1996, 74, 1168-1174.	6.4	18
112	Heparin and heparan sulfate proteoglycans promote HIV-1 p17 matrix protein oligomerization: computational, biochemical and biological implications. Scientific Reports, 2019, 9, 15768.	3.3	18
113	Subcellular Localization and Biological Activity of Mr 18,000 Basic Fibroblast Growth Factor: Site-Directed Mutagenesis of a Putative Nuclear Translocation Sequence. Growth Factors, 1993, 9, 269-278.	1.7	17
114	Urokinase-Type Plasminogen Activator Overexpression Enhances the Invasive Capacity of Endothelial Cells. Microvascular Research, 1997, 53, 254-260.	2.5	17
115	Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity. Sensors, 2009, 9, 6471-6503.	3.8	17
116	Characterization of the Effects of Two Polysulfonated Distamycin A Derivatives, PNU145156E and PNU153429, on HIV Type 1 Tat Protein. AIDS Research and Human Retroviruses, 1998, 14, 1561-1571.	1.1	16
117	Inhibition of intra- and extra-cellular Tat function and HIV expression by pertussis toxin B-oligomer. European Journal of Immunology, 2004, 34, 530-536.	2.9	16
118	Substrate-Immobilized HIV-1 Tat Drives VEGFR2/Î± _v Î² ₃ â€“Integrin Complex Formation and Polarization in Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, e25-34.	2.4	15
119	Sialic acid as a target for the development of novel antiangiogenic strategies. Future Medicinal Chemistry, 2018, 10, 2835-2854.	2.3	15
120	Chemoselective Surface Immobilization of Proteins through a Cleavable Peptide. Bioconjugate Chemistry, 2011, 22, 1753-1757.	3.6	14
121	Speeding Up the Identification of Cystic Fibrosis Transmembrane Conductance Regulator-Targeted Drugs: An Approach Based on Bioinformatics Strategies and Surface Plasmon Resonance. Molecules, 2018, 23, 120.	3.8	14
122	Inhibition of Eph/ephrin interaction with the small molecule UniPR500 improves glucose tolerance in healthy and insulin-resistant mice. Pharmacological Research, 2019, 141, 319-330.	7.1	13
123	The fd phage and a peptide derived from its p8 coat protein interact with the HIV-1 Tat-NLS and inhibit its biological functions. Antiviral Research, 2005, 66, 67-78.	4.1	12
124	Positively charged peptides can interact with each other, as revealed by solid phase binding assays. Analytical Biochemistry, 2006, 352, 157-168.	2.4	12
125	Functionalization of gold surfaces with copoly(DMA-NAS-MAPS) by dip coating: Surface characterization and hybridization tests. Sensors and Actuators B: Chemical, 2014, 190, 234-242.	7.8	12
126	A Bittersweet Computational Journey among Glycosaminoglycans. Biomolecules, 2021, 11, 739.	4.0	10

#	Article	IF	Citations
127	Upregulation of urokinase-type plasminogen activator by endogenous and exogenous HIV-1 Tat protein in tumour cell lines derived from BK virus/tat-transgenic mice. Aids, 1997, 11, 727-736.	2.2	8
128	Discovery of novel VX-809 hybrid derivatives as F508del-CFTR correctors by molecular modeling, chemical synthesis and biological assays. European Journal of Medicinal Chemistry, 2020, 208, 112833.	5.5	8
129	Examining New Models for the Study of Autocrine and Paracrine Mechanisms of Angiogenesis Through FGF2-Transfected Endothelial and Tumour Cells. Advances in Experimental Medicine and Biology, 2000, 476, 7-34.	1.6	8
130	Basic fibroblast growth factor bound to cell substrate promotes cell adhesion, proliferation, and protease production in cultured endothelial cells. Exs, 1992, 61, 205-209.	1.4	8
131	BSA conjugates bearing multiple copies of the basic domain of HIV-1 Tat: Prototype for the development of multitarget inhibitors of extracellular Tat. Antiviral Research, 2010, 87, 30-39.	4.1	7
132	Exploitation of a novel biosensor based on the full-length human F508del-CFTR with computational studies, biochemical and biological assays for the characterization of a new Lumacaftor/Tezacaftor analogue. Sensors and Actuators B: Chemical, 2019, 301, 127131.	7.8	7
133	Functional Domains of Basic Fibroblast Growth Factor: Possible Role of Asp-Gly-Arg Sequences in the Mitogenic Activity of bFGF. Annals of the New York Academy of Sciences, 1991, 638, 361-368.	3.8	6
134	Heparan Sulfate Proteoglycans: A Multifaceted Target for Novel Approaches in Antiviral Drug Discovery. Journal of Bioengineering & Biomedical Science, 2016, 06, .	0.2	6
135	Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis. Biochemical Pharmacology, 2016, 99, 18-30.	4.4	6
136	Recent Strategic Advances in CFTR Drug Discovery: An Overview. International Journal of Molecular Sciences, 2020, 21, 2407.	4.1	6
137	HIV-1 Tat and Heparan Sulfate Proteoglycans Orchestrate the Setup of in Cis and in Trans Cell-Surface Interactions Functional to Lymphocyte Trans-Endothelial Migration. Molecules, 2021, 26, 7488.	3.8	6
138	Critical role of gonadal hormones on the genotoxic activity of the hepatocarcinogen DL-ZAMI 1305. Cancer Letters, 1987, 36, 253-261.	7.2	5
139	A Monoclonal Antibody to the NH2-Terminal Region of Human Interferon-Î³ Inhibits Its Antiproliferative Activity Without Affecting Its Internalization. Journal of Interferon and Cytokine Research, 1995, 15, 197-204.	1.2	5
140	A CXCR1 haplotype hampers HIV-1 matrix protein p17 biological activity. Aids, 2014, 28, 2355-2364.	2.2	5
141	Syndecan-1 increases B-lymphoid cell extravasation in response to HIV-1 Tat via Î±vÎ²3/pp60src/pp125FAK pathway. Oncogene, 2017, 36, 2609-2618.	5.9	5
142	Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3Î±-carbamoyloxy derivative with antiangiogenetic properties. European Journal of Medicinal Chemistry, 2020, 189, 112083.	5.5	5
143	Surface Plasmon Resonance Analysis of Heparin-Binding Angiogenic Growth Factors. Methods in Molecular Biology, 2016, 1464, 73-84.	0.9	5
144	In silico drug repositioning on F508del-CFTR: A proof-of-concept study on the AIFA library. European Journal of Medicinal Chemistry, 2021, 213, 113186.	5.5	4

#	Article	IF	Citations
145	Cholenic acid derivative UniPR1331 impairs tumor angiogenesis via blockade of VEGF/VEGFR2 in addition to Eph/ephrin. Cancer Gene Therapy, 2022, 29, 908-917.	4.6	4
146	A Mutant of Basic Fibroblast Growth Factor that Has Lost the Ability to Stimulate Plasminogen Activator Synthesis in Endothelial Cells. Annals of the New York Academy of Sciences, 1991, 638, 369-377.	3.8	3
147	Alterations of blood vessel development by endothelial cells overexpressing fibroblast growth factorÃ¢Â€Â². Journal of Pathology, 1999, 189, 590-599.	4.5	3
148	Fibroblast Growth Factor-2 in Angiogenesis. , 2008, , 77-88.		2
149	Basic Fibroblast Growth Factor Expression in Endothelial Cells: An Autocrine Role in Angiogenesis?. , 1996, , 61-72.		2
150	Metabolic Soft Spot and Pharmacokinetics: Functionalization of C-3 Position of an Ephâ€“Ephrin Antagonist Featuring a Bile Acid Core as an Effective Strategy to Obtain Oral Bioavailability in Mice. Pharmaceuticals, 2022, 15, 41.	3.8	2
151	Liver DNA Damage by Chemical Carcinogens: Role of Thyroid Hormones. , 1988, , 129-135.		1
152	The Interaction of Basic Fibroblast Growth Factor (bFGF) With Heparan Sulfate Proteoglycans. , 1996, , 171-187.		1
153	Prevention of Herpesviridae Infections by Cationic PEGylated Carbosilane Dendrimers. Pharmaceutics, 2022, 14, 536.	4.5	1
154	Heparin Derivatives and Semisynthetic Biotechnological Heparins as Angiogenesis Inhibitors. Frontiers in Drug Design and Discovery, 2005, 2, 371-391.	0.3	0
155	FGF Ligand Traps for the Therapy of FGF-Dependent Tumors. , 2017, , 237-269.		0
156	Interaction of Angiogenic Growth Factors with Endothelial Cell Heparan Sulfate Proteoglycans. , 2002, , 357-385.		0
157	Basic Fibroblast Growth Factor and Endothelial Cells: Receptor Interaction, Signal Transduction, Cellular Response-Dissociation of the Mitogenic Activity of bFGF from its Plasminogen Activator-Inducing Capacity. , 1992, , 79-89.		0
158	Human Basic Fibroblast Growth Factor: Structure-Function Relationship of an Angiogenic Molecule. , 1994, , 39-50.		0
159	Autocrine Role of Basic Fibroblast Growth Factor (bFGF) in Angiogenesis and Angioproliferative Diseases. , 1998, , 99-112.		0